Halozyme Therapeutics Aktie

56,98 EUR +0,70 EUR +1,24 %

14.03.2025

FSE

62,24 USD +1,20 USD +1,97 %

nachbörslich14.03.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.7,05 Mrd. EUR

KGV13,93Div. Rendite0,00%

WKNA0DLHS

ISINUS40637H1095

SymbolHALO

Halozyme Therapeutics Aktien News

Sortieren:Datum Meistgelesen

09.07.24ZacksIs Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"

08.07.24ZacksWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

25.06.24PR NewswireHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

24.06.24BenzingaDecoding 12 Analyst Evaluations For Halozyme Therapeutics

21.06.24PR NewswireHalozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

17.06.24ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

11.06.24ZacksHalozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?

06.06.24BenzingaHalozyme Therapeutics +13% On Thursday: What's Going On?

06.06.24ZacksHalozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?

06.06.24PR NewswireHalozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

05.06.24PR NewswireHalozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform

04.06.24PR NewswireHalozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

04.06.24BenzingaA Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts

31.05.24ZacksWhy Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

21.05.24PR NewswireHalozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

20.05.24ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

16.05.24ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

08.05.24PR NewswireHalozyme to Participate in Upcoming Investor Conferences

08.05.24ZacksHalozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

07.05.24ZacksHalozyme Therapeutics (HALO) Q1 Earnings Beat Estimates

07.05.24PR NewswireHALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS

07.05.24BenzingaExpert Ratings For Halozyme Therapeutics

06.05.24ZacksHalozyme Therapeutics (HALO) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

30.04.24ZacksHalozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

25.04.24PR NewswireMahesh Krishnan Elected to Halozyme's Board of Directors

24.04.24ZacksWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

23.04.24PR NewswireHalozyme to Report First Quarter 2024 Financial and Operating Results

18.04.24ZacksHalozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

18.04.24ZacksHalozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know

16.04.24Benzinga9 Analysts Have This To Say About Halozyme Therapeutics

04.04.24ZacksHalozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

21.03.24ZacksWhy Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?

19.03.24ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

27.02.24PR NewswireHalozyme to Participate in Upcoming Investor Conferences

20.02.24PR NewswireHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS

08.02.24PR NewswireHalozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results

29.01.24PR NewswireHalozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

18.01.24PR NewswireHalozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis

16.01.24PR NewswireHalozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

16.01.24PR NewswireHalozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types

Halozyme Therapeutics News

Halozyme Therapeutics News: auf dieser Seite finden Sie alle Halozyme Therapeutics News und Nachrichten zur Halozyme Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Halozyme Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Halozyme Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.